Azasite Solution/ Drops
NDC Package 82584-307-03
Package Information
Azasite (azithromycin monohydrate) solution/ dropses is a medication used to treat certain eye infections. This formulation utilizes a solution/ drops delivery system. Marketed by Thea Pharma Inc., this product is identified by NDC 82584-307 and is authorized under FDA application NDA050810.
Identification & Billing
- RxCUI: 706868 - azithromycin 1 % Ophthalmic Solution
- RxCUI: 706868 - azithromycin 10 MG/ML Ophthalmic Solution
- RxCUI: 706868 - azithromycin (as azithromycin monohydrate) 10 MG/ML Ophthalmic Solution
- RxCUI: 706872 - AzaSite 1 % Ophthalmic Solution
- RxCUI: 706872 - azithromycin 10 MG/ML Ophthalmic Solution [AzaSite]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82584 - Thea Pharma Inc.
- 82584-307 - Azasite
- 82584-307-03 - 1 BOTTLE, DROPPER in 1 CARTON / 2.5 mL in 1 BOTTLE, DROPPER
- 82584-307 - Azasite
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (82584-307). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82584-307-03 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 2.5 ml in 1 bottle, dropper of Azasite, a human prescription drug labeled by Thea Pharma Inc.. This solution/ drops is formulated for ophthalmic use and contains azithromycin monohydrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Thea Pharma Inc. on November 01, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.
How is this Thea Pharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82584030703. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.